Excerpts

In the FET hotspot analysis, the best similarity (good agreement) with GTV 2 was found in the G1 group using a 90% SUVmax delineation method and showed a trend of statistical difference with those (poor agreement) in the G2 group (OV’ = 0.67 vs. 0.38, respectively, p = 0.068); whereas the best similarity (good agreement) with GTV 3 was found in the G1 group using a 80% SUVmax delineation method and was significantly higher than those (poor agreement) in the G2 group (OV’= 0.72 vs. 0.35, respectively, p = 0.014).

In addition, a marginal significance was found with patients drinking less than 7 drinks per week, with an OR of 4.1786 (95% CI 0.8995–19.4103, p = 0.0680).

CTP A patients in the nivolumab arm showed a trend to longer mOS, with 31.2 months (95% CI: 12.6–72.8) compared to 14.2 months (95% CI: 1.9–26.5) in the sorafenib only arm (HR 1.80; 95% CI: 0.95–3.44, p = 0.068; Figure 2 A).

high-grade DDIs had better outcomes in terms of OS ( p = 0.0012) and a trend toward significance in PFS ( p = 0.068).

30.2%, p = 0.197); however, a statistical trend ( p = 0.068) in favour of adjuvant treatment exists when considering overall disease free survival (16 months (IQR: 10.5–27) vs. 14 months (IQR: 9–22)).

Only a statistical trend was observed for cancer type ( p = 0.068), further supporting the notion that exceptional adaptation is less dependent on medical characteristics of the disease.

These ACT experiments showed an identical (almost significant: p = 0.0685) protective effect of the cells primed with either GL261-WT or -CIITA-expressing cells with respect to the transfer of cells from sham-operated mice.

3.12, n = 76, p = 0.0257) but not in the M or LAR subtypes, and showed a trend (H.R. 1.57, n = 171, p = 0.0687) towards poorer outcome in the BL-1 subtype ( Table 1 ) [ 43 ].

In the present study, we found a statistically significant association between pretreatment NLR and OS using a cutoff value of ≥2 and a strong trend toward association with a cutoff value of ≥5 ( p = 0.069).

In the <45 year group (6 studies, 10 observations), the best-fitting model was linear, with an intercept of 65.45 ( p < 0.001) and a positive but borderline non-significant slope (β = 0.18, p = 0.069).

63%, p < 0.001, Figure 1 D); adjuvant therapies after lung metastasectomy had only a trend towards significance ( p = 0.069).

Multivariable analysis revealed that treatment modality had little impact on both LRC and OS; only GTV ≥ 100 cc showed borderline significance in LRC (HR 1.74, p = 0.069, Table 2 ). 3.4.

Likewise, patients harboring the KL status and concomitant no/low β-catenin membranous expression showed a trend correlating with decreased mOS vs. patients of KL status with retained, medium–high β-catenin membranous expression: 20.07 vs. 52.99; p = 0.069, Supplementary Table S20 . 3.6.7.

7.2 years; p = 0.001) and showed a trend for a correlation with shorter disease-free survival (median estimate 13.7 years vs. 9.7 years; p = 0.069) time after diagnosis ( Figure 2 ). 2.3.

There was, however, a trend towards significance between the PET and the CT data ( p -value = 0.070).

Interestingly, δ 13 C measured in tumor tissue showed only a nonsignificant trend toward shorter DFS (HR 1.44, 95% CI 0.97–2.14, p = 0.07), while δ 13 C tumor–margin differences were not associated with DFS.

In addition, the MoRAL score showed the best calibration function with a non-significant p value ( p = 0.15) by the Hosmer-Lemeshow test; the WCM model and the AFP model, the second and third best models evaluated by c -index, were found to be less accurate with marginally significant p values ( p = 0.07, and p = 0.06, respectively).

Additionally, IGF1R mutations exhibited borderline significance (7.2% vs. 2.9%, p = 0.07).

However, it is striking that nuclear/cytoplasmic expression of β-catenin has not been shown by itself in this meta-analysis to be significantly associated with poor survival, although a marked trend of effect is shown ( p = 0.07); this result is probably due to the paucity of primary studies addressing this question (3 studies, 255 patients).

In contrast, male sex, allogeneic HSCT, hypertension, diabetes, BMI ≥ 25, and smoking were not independently associated, although hypertension showed a nonsignificant trend toward increased risk (OR 1.34; 95% CI 0.98–1.82; p = 0.07) ( Table 8 , Figure 4 ).

Patients with small lesions (maximum diameter <5 cm) showed a trend toward a higher OS rate ( p = 0.07).

CDX2 was near statistical significance for DFS (HR = 2.15, 95% CI (0.92–5.04), p = 0.070).

We observed a borderline significant link between G grade and recurrence ( p = 0.07) with a higher probability of recurrence for the G3 stage.

Positive PD-L1 staining determined at a threshold of 1% showed a trend towards improved survival in the entire cohort (70.3% vs. 57.4%, p = 0.07) in univariate analysis ( Figure 2 ).

First, we looked at CR/CRi status at FU90 and found a trend for an association of chromatin-modifier mutations with a higher CR/CRi rate ( p = 0.07), whereas mutations in tumor-suppressor genes showed a trend for a lower CR/CRi rate ( p = 0.07) ( Supplementary Table S4 ).